vitamin-k-semiquinone-radical and Vascular-Diseases

vitamin-k-semiquinone-radical has been researched along with Vascular-Diseases* in 28 studies

Reviews

8 review(s) available for vitamin-k-semiquinone-radical and Vascular-Diseases

ArticleYear
Vitamin K status, supplementation and vascular disease: a systematic review and meta-analysis.
    Heart (British Cardiac Society), 2019, Volume: 105, Issue:12

    Vascular stiffness (VS) and vascular calcification (VC) are surrogate markers of vascular health associated with cardiovascular events. Vitamin K-dependent proteins (VKDP) are associated with VS and VC and require vitamin K for activity. We conducted a systematic review and meta-analysis of: (1) the effect of vitamin K supplementation on VS and VC and (2) association of inactive VKDP levels with incident cardiovascular disease and mortality.. Two authors searched MEDLINE and Embase databases and Cochrane and ISRCTN registries for studies of vitamin K clinical trials that measured effects on VC, VS or VKDP and longitudinal studies assessing effect of VKDP on incident CVD or mortality. Random effects meta-analyses were performed.. Thirteen controlled clinical trials (n=2162) and 14 longitudinal studies (n=10 726) met prespecified inclusion criteria. Vitamin K supplementation was associated with significant reduction in VC (-9.1% (95% CI -17.7 to -0.5); p=0.04) and VKDP (desphospho-uncarboxylated matrix Gla protein; -44.7% (95% CI -65.1 to -24.3), p<0.0001) and uncarboxylated osteocalcin; -12.0% (95% CI -16.7 to -7.2), p<0.0001) compared with control, with a non-significant improvement in VS. In longitudinal studies with median follow-up of 7.8 (IQR 4.9-11.3) years, VKDP levels were associated with a combined endpoint of CVD or mortality (HR 0.45 (95% CI 0.07 to 0.83), p=0.02).. Supplementation with vitamin K significantly reduced VC, but not VS, compared with control. The conclusions drawn are limited by small numbers of studies with substantial heterogeneity. VKDP was associated with combined endpoint of CVD or mortality. Larger clinical trials of effect of vitamin K supplementation to improve VC, VS and long-term cardiovascular health are warranted.. CRD42017060344.

    Topics: Biomarkers; Dietary Supplements; Humans; Vascular Calcification; Vascular Diseases; Vitamin K; Vitamins

2019
Prevention of vasculopathy by vitamin K supplementation: can we turn fiction into fact?
    Atherosclerosis, 2015, Volume: 240, Issue:1

    With the discovery that vitamin K-dependent matrix Gla-protein (MGP) is a strong and modifiable factor in the prevention of arterial calcification, vitamin K was put forward as novel treatment option in cardiovascular disease. The vasculoprotective properties of vitamin K are in part based on the ability to improve gamma-glutamylcarboxylation of MGP, which is a prerequisite for MGP as a calcification inhibitor. Data from experimental animal models reveal that high intake of vitamin K can prevent and even reverse vascular calcifications. In addition, clinical data demonstrate that prescription of vitamin K antagonists for long-term oral anticoagulant therapy accelerates vascular calcification. However, controlled data from randomized prospective vitamin K interventional trials are lacking, thereby weakening a general recommendation for supplementation. The present article summarizes our current knowledge on the association between vitamin K and cardiovascular health. Additionally, we focus on an outlook on important ongoing prospective vitamin K intervention studies. These studies address the issues whether vitamin K substitution helps modifying relevant cardiovascular surrogates such as vascular calcification and whether non-vitamin K oral anticoagulants provide an alternative to support cardiovascular health benefits. So research about cardiovascular protection by vitamin K is an evolving field in which we expect a boost of novel and relevant evidence shortly.

    Topics: Animals; Anticoagulants; Atherosclerosis; Dietary Supplements; Humans; Osteocalcin; Protective Factors; Risk Assessment; Risk Factors; Treatment Outcome; Vascular Calcification; Vascular Diseases; Vitamin K; Vitamin K Deficiency

2015
Vitamin K status in chronic kidney disease: a report of a study and a mini-review.
    International urology and nephrology, 2013, Volume: 45, Issue:5

    Hepatic vitamin K-dependent proteins (e.g., Factors II, VII, IX and X) form part of the clotting cascade. Factor II (FII)/Prothrombin incorporates 10 Glu residues on the N-terminal region that are γ-carboxylated to Gla residues by the action of γ-glutamyl carboxylase to confer biological activity. Vitamin K is also required for the normal function of Matrix Gla Protein (MGP)--one of several non-clotting-related extra-hepatic vitamin K-dependent proteins. MGP is known to have protective action against vascular calcification--indeed it is a powerful tissue-bound inhibitory mechanism and can be found in blood vessel walls. The mature protein is also dependent on activation by γ-glutamyl carboxylase enzyme to convert Glu residues in its amino acid sequence to Gla. This reaction can only take place when the enzyme is activated in the presence of vitamin K. It is of great potential interest to investigate whether subtle deficiencies of vitamin K may, through its effect on the action of MGP, be a contributing factor to vascular calcification in CKD patients, in whom CV disease is greatly accelerated and in whom vascular calcification is not only common, but progresses aggressively, and is something for which as yet there is no clinically applicable remedy.

    Topics: Adult; Aged; Biomarkers; Calcinosis; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Protein Precursors; Prothrombin; Renal Insufficiency, Chronic; Vascular Diseases; Vitamin K; Vitamin K Deficiency

2013
Vitamin K-dependent proteins, warfarin, and vascular calcification.
    Clinical journal of the American Society of Nephrology : CJASN, 2008, Volume: 3, Issue:5

    Vitamin K-dependent proteins (VKDPs) require carboxylation to become biologically active. Although the coagulant factors are the most well-known VKDPs, there are many others with important physiologic roles. Matrix Gla Protein (MGP) and Growth Arrest Specific Gene 6 (Gas-6) are two particularly important VKDPs, and their roles in vascular biology are just beginning to be understood. Both function to protect the vasculature; MGP prevents vascular calcification and Gas-6 affects vascular smooth muscle cell apoptosis and movement. Unlike the coagulant factors, which undergo hepatic carboxylation, MGP and Gas-6 are carboxylated within the vasculature. This peripheral carboxylation process is distinct from hepatic carboxylation, yet both are inhibited by warfarin administration. Warfarin prevents the activation of MGP and Gas-6, and in animals, induces vascular calcification. The relationship of warfarin to vascular calcification in humans is not fully known, yet observational data suggest an association. Given the high risk of vascular calcification in those patients with chronic kidney disease, the importance of understanding warfarin's effect on VKDPs is paramount. Furthermore, recognizing the importance of VKDPs in vascular biology will stimulate new areas of research and offer potential therapeutic interventions.

    Topics: Animals; Anticoagulants; Blood Vessels; Calcinosis; Calcium-Binding Proteins; Extracellular Matrix Proteins; Humans; Intercellular Signaling Peptides and Proteins; Kidney Failure, Chronic; Matrix Gla Protein; Protein Processing, Post-Translational; Risk Assessment; Risk Factors; Vascular Diseases; Vitamin K; Warfarin

2008
Mechanisms of vascular calcification.
    Advances in chronic kidney disease, 2007, Volume: 14, Issue:1

    Vascular calcification is highly prevalent and correlated with high rates of cardiovascular mortality in chronic kidney disease patients. Recent evidence suggests that mineral, hormonal, and metabolic imbalances that promote phenotype change in vascular cells as well as deficiencies in specific mineralization inhibitory pathways may be important contributory factors for vascular calcification in these patients. This article reviews current mechanisms proposed for the regulation of vascular calcification and data supporting their potential contribution to this process in chronic kidney disease.

    Topics: alpha-2-HS-Glycoprotein; Animals; Antifibrinolytic Agents; Blood Proteins; Bone Density Conservation Agents; Bone Morphogenetic Proteins; Calcinosis; Calcium-Binding Proteins; Chronic Disease; Extracellular Matrix Proteins; Humans; Kidney Diseases; Kidney Failure, Chronic; Matrix Gla Protein; Mice; Parathyroid Hormone; Phosphates; Rats; Vascular Diseases; Vitamin D; Vitamin K

2007
Vascular calcification in chronic kidney disease: the role of vitamin K.
    Nature clinical practice. Nephrology, 2007, Volume: 3, Issue:10

    Topics: Animals; Anticoagulants; Calcinosis; Chronic Disease; Humans; Renal Dialysis; Renal Insufficiency; Vascular Diseases; Vitamin K; Vitamin K Deficiency; Warfarin

2007
Role of K vitamins in the regulation of tissue calcification.
    Journal of bone and mineral metabolism, 2001, Volume: 19, Issue:4

    Topics: Animals; Arteries; Calcification, Physiologic; Calcinosis; Calcium-Binding Proteins; Cartilage; Extracellular Matrix Proteins; Humans; Matrix Gla Protein; Nutritional Requirements; Organ Specificity; Osteogenesis; Vascular Diseases; Vitamin K

2001
Role of vitamin K and Gla proteins in the pathophysiology of osteoporosis and vascular calcification.
    Current opinion in clinical nutrition and metabolic care, 2000, Volume: 3, Issue:6

    Among the proteins known or suspected to be involved in bone and vascular biology are several members of the vitamin K-dependent or Gla protein family. This review focuses on the role of two of these: osteocalcin and matrix Gla protein. Osteocalcin metabolism has been implicated in the pathogenesis of osteoporosis through an unknown mechanism that may be linked to suboptimal vitamin K status resulting in its undercarboxylation and presumed dysfunction. Recent studies that have investigated this hypothesis are discussed, as are recent promising clinical studies of vitamin K supplementation in osteoporosis. A recently delineated function of matrix Gla protein is as a powerful inhibitor of calcification of arteries and cartilage. In the period covered by this review there have been several landmark studies using cell systems, whole animals and genetic techniques that have consolidated and extended our knowledge of the role of matrix Gla protein in the prevention of ectopic calcification.

    Topics: Bone and Bones; Calcinosis; Humans; Osteocalcin; Osteoporosis; Vascular Diseases; Vitamin K

2000

Trials

2 trial(s) available for vitamin-k-semiquinone-radical and Vascular-Diseases

ArticleYear
Effect of Vitamin K on Vascular Health and Physical Function in Older People with Vascular Disease--A Randomised Controlled Trial.
    The journal of nutrition, health & aging, 2016, Volume: 20, Issue:3

    Vitamin K insufficiency is common and linked to an increased risk of cardiovascular disease and osteoporotic fractures. The aim of this study was to examine whether daily supplementation with oral vitamin K could improve vascular health and physical function in older people with established vascular disease.. A double blind, randomised, placebo-controlled trial. Participants aged ≤ 70 years with a history of vascular disease were randomised to receive 6 months of daily oral 100mcg vitamin K2 (MK7 subtype) or matching placebo with outcomes measured at 0, 3 and 6 months. The primary outcome was between-group difference in endothelial function assessed using flow-mediated dilatation of the brachial artery at 6 months. Secondary outcomes included carotid-radial pulse wave velocity, augmentation index, blood pressure, carotid intima-media thickness, C-reactive protein, B-type natriuretic peptide, cholesterol and desphospho-uncarboxylated matrix Gla protein levels. Handgrip strength and the Short Physical Performance Battery assessed physical function, while postural sway was measured using a 3-dimensional force platform.. 80 participants were randomised, mean age 77 (SD 5) years; 44/80 were male. Vitamin K levels rose in the intervention arm compared to placebo (+48 pg/ml vs -6 pg/ml, p=0.03) at 6 months. Desphospho-uncarboxylated Matrix Gla protein levels fell in the intervention group compared to placebo at 6 months (-130 [SD 117] pmol/L vs +13 [SD 180] pmol/L, p<0.001). No change was seen in endothelial function (between group difference -0.3% [95%CI -1.3 to 0.8], p=0.62). A modest, non-significant improvement in pulse wave velocity was seen in the vitamin K group (-0.8m/s [95%CI -1.8 to 0.3], p=0.15) while all other vascular and physical function outcomes unchanged.. Six months of vitamin K2 supplementation did not improve markers of vascular health or physical function in older patients with vascular disease.

    Topics: Aged; Biomarkers; Blood Pressure; Brachial Artery; C-Reactive Protein; Carotid Intima-Media Thickness; Cholesterol; Dietary Supplements; Double-Blind Method; Female; Hand Strength; Humans; Male; Natriuretic Peptide, Brain; Pulse Wave Analysis; Treatment Failure; Vascular Diseases; Vitamin K

2016
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead. We investigated the hypothesis that the addition of clopidogrel to aspirin would reduce the risk of vascular events in patients with atrial fibrillation.. A total of 7554 patients with atrial fibrillation who had an increased risk of stroke and for whom vitamin K-antagonist therapy was unsuitable were randomly assigned to receive clopidogrel (75 mg) or placebo, once daily, in addition to aspirin. The primary outcome was the composite of stroke, myocardial infarction, non-central nervous system systemic embolism, or death from vascular causes.. At a median of 3.6 years of follow-up, major vascular events had occurred in 832 patients receiving clopidogrel (6.8% per year) and in 924 patients receiving placebo (7.6% per year) (relative risk with clopidogrel, 0.89; 95% confidence interval [CI], 0.81 to 0.98; P=0.01). The difference was primarily due to a reduction in the rate of stroke with clopidogrel. Stroke occurred in 296 patients receiving clopidogrel (2.4% per year) and 408 patients receiving placebo (3.3% per year) (relative risk, 0.72; 95% CI, 0.62 to 0.83; P<0.001). Myocardial infarction occurred in 90 patients receiving clopidogrel (0.7% per year) and in 115 receiving placebo (0.9% per year) (relative risk, 0.78; 95% CI, 0.59 to 1.03; P=0.08). Major bleeding occurred in 251 patients receiving clopidogrel (2.0% per year) and in 162 patients receiving placebo (1.3% per year) (relative risk, 1.57; 95% CI, 1.29 to 1.92; P<0.001).. In patients with atrial fibrillation for whom vitamin K-antagonist therapy was unsuitable, the addition of clopidogrel to aspirin reduced the risk of major vascular events, especially stroke, and increased the risk of major hemorrhage. (ClinicalTrials.gov number, NCT00249873.)

    Topics: Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Embolism; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk; Stroke; Ticlopidine; Vascular Diseases; Vitamin K

2009

Other Studies

18 other study(ies) available for vitamin-k-semiquinone-radical and Vascular-Diseases

ArticleYear
The abnormal status of uncarboxylated matrix Gla protein species represents an additional mortality risk in heart failure patients with vascular disease.
    International journal of cardiology, 2016, Jan-15, Volume: 203

    Matrix Gla protein (MGP) is a natural inhibitor of tissue calcification. In a previous study, we observed the positive association between abnormal concentrations of uncarboxylated MGP species and increased mortality risk in stable vascular patients. We explore whether co-incidence of abnormal status of uncarboxylated MPG and heart failure (HF) affects the mortality risk.. We examined 799 patients (mean age 65.1 years) with stable vascular disease and followed them in a prospective study. Both, desphospho-uncarboxylated and total uncarboxylated MGP (dp-ucMGP or t-ucMGP) were quantified by pre-commercial ELISA assays.. Elevated (>100 ng/L) circulating brain natriuretic peptide (BNP) and abnormal status of plasma uncarboxylated MGP species (i.e.: dp-ucMGP ≥ 977 pmol/L or t-ucMGP ≤ 2825 nmol/L) were all identified as robust predictors of all-cause 5-year mortality. However, their co-incidence represented a substantial additional risk. We observed the highest mortality risk in patients with elevated BNP plus high dp-ucMGP compared to those with normal BNP plus low dp-ucMGP; fully adjusted HRR's were 4.86 (3.15-7.49). Likewise, the risk was increased when compared with patients with elevated BNP plus low dp-ucMGP; HRR 2.57 (1.60-4.10). Similar result we observed when co-incidence of elevated BNP and low t-ucMGP was analyzed [corresponding HRR's were 4.16 (2.62-6.61) and 1.96 (1.24-3.12)].. The concomitant abnormality of uncarboxylated MGP and mild elevation of BNP leads in chronic patients with vascular disease to about two-fold increase of the relative mortality risk. We hypothesize that abnormal homeostasis of MGP is involved in the pathophysiology of HF.

    Topics: Aged; Biomarkers; Calcinosis; Calcium-Binding Proteins; Czech Republic; Extracellular Matrix Proteins; Female; Follow-Up Studies; Heart Failure; Humans; Male; Matrix Gla Protein; Prospective Studies; Risk Assessment; Risk Factors; Survival Rate; Vascular Diseases; Vitamin K

2016
Reasons for and consequences of vitamin K antagonist discontinuation in very elderly patients with non-valvular atrial fibrillation.
    Journal of thrombosis and haemostasis : JTH, 2016, Volume: 14, Issue:11

    Essentials Anticoagulation in the elderly is still a challenge and suspension of warfarin is common. This is an observational study reporting reasons and consequences of warfarin suspension. Vascular disease, age, time in therapeutic range, and bleedings are associated with suspension. After suspension for bleeding or frailty, patients remain at high-risk of death or complications.. Background Anticoagulation in elderly patients with non-valvular atrial fibrillation (NVAF) is still a challenge, and discontinuation of warfarin is common. The aim of this study was to analyze the aspects related to warfarin discontinuation in a real-world population. Methods This was an observational cohort study on very elderly NVAF patients naive to warfarin therapy (VENPAF). The included subjects were aged at least 80 years, and started using warfarin after a diagnosis of NVAF. Warfarin discontinuation was assessed, and the reason reported for discontinuation, the person who decided to stop treatment, subsequent antithrombotic therapy and mortality, ischemic and bleeding events were collected. Results Over a period of 5 years, warfarin was discontinued in 148 of 798 patients. Despite similar CHA

    Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Female; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Humans; Male; Multivariate Analysis; Proportional Hazards Models; Risk Factors; Stroke; Thromboembolism; Treatment Outcome; Vascular Diseases; Vitamin K; Warfarin

2016
Differential Effects of Dabigatran and Warfarin on Bone Volume and Structure in Rats with Normal Renal Function.
    PloS one, 2015, Volume: 10, Issue:8

    Warfarin, a widely used anticoagulant, is a vitamin K antagonist impairing the activity of vitamin K-dependent Bone Gla Protein (BGP or Osteocalcin) and Matrix Gla Protein (MGP). Because dabigatran, a new anticoagulant, has no effect on vitamin K metabolism, the aim of this study was to compare the impact of warfarin and dabigatran administration on bone structure and vascular calcification.. Rats with normal renal function received for 6 weeks warfarin, dabigatran or placebo. Bone was evaluated immuno-histochemically and hystomorphometrically after double labelling with declomycin and calcein. Aorta and iliac arteries were examined histologically.. Histomorphometric analysis of femur and vertebrae showed significantly decreased bone volume and increased trabecular separation in rats treated with warfarin. Vertebra analysis showed that the trabecular number was higher in dabigatran treated rats. Osteoblast activity and resorption parameters were similar among groups, except for maximum erosion depth, which was higher in warfarin treated rats, suggesting a higher osteoclastic activity. Therefore, warfarin treatment was also associated with higher bone formation rate/bone surface and activation frequency. Warfarin treatment may cause an increased bone turnover characterized by increased remodelling cycles, with stronger osteoclast activity compared to the other groups. There were no differences among experimental groups in calcium deposition either in aortic or iliac arteries.. These findings suggest for the first time that dabigatran has a better bone safety profile than warfarin, as warfarin treatment affects bone by reducing trabecular size and structure, increasing turnover and reducing mineralization. These differences could potentially result in a lower incidence of fractures in dabigatran treated patients.

    Topics: Animals; Anticoagulants; Antithrombins; Aorta; Bone and Bones; Bone Diseases, Metabolic; Bone Remodeling; Calcinosis; Dabigatran; Female; Fractures, Spontaneous; Iliac Artery; Kidney; Minerals; Osteoblasts; Osteoclasts; Random Allocation; Rats; Rats, Sprague-Dawley; Vascular Diseases; Vitamin K; Warfarin

2015
Desphospho-uncarboxylated matrix Gla-protein is associated with mortality risk in patients with chronic stable vascular disease.
    Atherosclerosis, 2014, Volume: 235, Issue:1

    Vitamin K is the essential co-factor for activation of matrix Gla-protein (MGP), the natural inhibitor of tissue calcification. Biologically inactive, desphospho-uncarboxylated MGP (dp-ucMGP) is a marker of vascular vitamin K status and is described to predict mortality in patients with heart failure and aortic stenosis. We hypothesized that increased dp-ucMGP might be associated with mortality risk in clinically stable patients with chronic vascular disease.. We examined 799 patients (mean age 65.1 ± 9.3 years) who suffered from myocardial infarction, coronary revascularization or first ischemic stroke (pooled Czech samples of EUROASPIRE III and EUROASPIRE-stroke surveys), and followed them in a prospective cohort study. To estimate the 5-year all-cause and cardiovascular mortality we ascertained vital status and declared cause of death. Circulating dp-ucMGP and desphospho-carboxylated MGP (dp-cMGP) were measured by ELISA methods (IDS and VitaK).. During a median follow-up of 2050 days (5.6 years) 159 patients died. In the fully adjusted multivariate Cox proportional hazard model, the patients in the highest quartile of dp-ucMGP (≥ 977 pmol/L) had higher risk of all-cause and cardiovascular 5-year mortality [HRR 1.89 (95% CI, 1.32-2.72) and 1.88 (95% CI, 1.22-2.90)], respectively. Corresponding HRR for dp-cMGP were 1.76 (95% CI, 1.18-2.61) and 1.79 (95% CI, 1.12-2.57).. In patients with overt vascular disease, circulating dp-ucMGP and dp-cMGP were independently associated with the risk of all-cause and cardiovascular mortality. Since published results are conflicting regarding the dp-cMGP, we propose only circulating dp-ucMGP as a potential biomarker for assessment of additive cardiovascular risk.

    Topics: Aged; Biomarkers; Calcium-Binding Proteins; Cardiovascular Diseases; Enzyme-Linked Immunosorbent Assay; Extracellular Matrix Proteins; Female; Humans; Kaplan-Meier Estimate; Male; Matrix Gla Protein; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Proportional Hazards Models; Prospective Studies; Regression Analysis; Stroke; Treatment Outcome; Vascular Diseases; Vitamin K

2014
Vitamin K and vascular calcifications.
    Acta physiologica Hungarica, 2010, Volume: 97, Issue:3

    The role of vitamin K in the synthesis of some coagulation factors is well known. The implication of vitamin K in vascular health was demonstrated in many surveys and studies conducted over the past years on the vitamin K-dependent proteins non-involved in coagulation processes. The vitamin K-dependent matrix Gla protein is a potent inhibitor of the arterial calcification, and may become a non-invasive biochemical marker for vascular calcification. Vitamin K(2) is considered to be more important for vascular system, if compared to vitamin K(1). This paper is reviewing the data from recent literature on the involvement of vitamin K and vitamin K-dependent proteins in cardiovascular health.

    Topics: Animals; Blood Coagulation; Calcinosis; Calcium-Binding Proteins; Extracellular Matrix Proteins; Humans; Matrix Gla Protein; Vascular Diseases; Vitamin K

2010
Matrix-Gla protein and vascular calcification: the negative role of oral anticoagulant therapy.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:4

    Topics: Administration, Oral; Animals; Anticoagulants; Aortic Valve; Biomarkers; Calcinosis; Calcium-Binding Proteins; Chronic Disease; Down-Regulation; Extracellular Matrix Proteins; Glomerular Filtration Rate; Heart Valve Diseases; Humans; Kidney Diseases; Matrix Gla Protein; Prognosis; Vascular Diseases; Vitamin K

2009
Vitamin K intake and calcifications in breast arteries.
    Maturitas, 2007, Mar-20, Volume: 56, Issue:3

    Vitamin K is an important co-factor in the production of proteins that inhibit vascular calcification. A low dietary Vitamin K intake has been associated with aortic and coronary calcifications and an elevated cardiovascular risk. Calcifications in the arteries of the breasts have also been associated with cardiovascular risk, but whether there is a relation with a low Vitamin K intake has not yet been studied.. We conducted a cross-sectional study among 1689 women, aged 49-70 years. Dietary Vitamins K1 and K2 intake was calculated from a validated food frequency questionnaire. Breast arterial calcifications (BAC) were assessed on standard screening mammograms by two independent radiologists. With a general linear model mean Vitamins K1, K2 and Vitamin K2 subtypes were calculated for women with BAC and without, adjusted for age, smoking, diabetes, intake of saturated fat, mono-unsaturated fat, poly-unsaturated fat and protein- and calcium-intake.. BAC was less common in the highest (9%) quartile of Vitamin K2 intake, compared to the lowest (13%) (OR 0.7, 95% CI 0.5-1.1) and not different across quartiles of Vitamin K1 intake. Mean Vitamin K2 levels and mean levels of Vitamin K2 subtypes MK-5 through MK-10 were lower in the participants with BAC (p=0.01) compared to participants without BAC. However, after adjustment for aging, smoking, diabetes and dietary factors the association of mean Vitamin K2 intake with BAC was no longer significant.. Calcifications in breast arteries are not associated with a lower dietary intake of Vitamin K.

    Topics: Aged; Calcinosis; Cross-Sectional Studies; Diet Records; Europe; Female; Humans; Mammary Arteries; Mammography; Middle Aged; Nutritional Status; Prospective Studies; Vascular Diseases; Vitamin K; Vitamin K Deficiency

2007
Is there a role for reactive oxygen species in arterial medial elastocalcinosis?
    Vascular pharmacology, 2007, Volume: 46, Issue:3

    Isolated systolic hypertension results from a gradual stiffening of large arteries, to which medial elastocalcinosis (calcification of elastic lamellae) contributes. There is compelling evidence that reactive oxygen species (ROS) are associated with several disease processes affecting the cardiovascular system, including hypertension. The present study was designed to investigate whether the inhibition of ROS production by alpha-lipoic acid can prevent vascular calcification. Sprague-Dawley rats were treated with warfarin (20 mg/kg/day) and vitamin K (15 mg/kg/day) (WVK) for 4 weeks to induce large artery calcification. Subgroups received either a normal diet or a diet supplemented with lipoic acid (1000 mg/kg/day). The WVK treatment produced a small elevation of aortic superoxide levels that did not reach statistical significance. Alpha-lipoic acid reduced the elevation below baseline levels. In rats treated with alpha-lipoic acid, the WVK-induced elevation of pulse wave velocity (an index of arterial stiffness), left ventricular hypertrophy, and aortic, femoral and carotid elastocalcinosis were not prevented. Although a contribution of oxidative stress has been suggested in the aging cardiovascular system, this alteration does not appear to contribute to the calcification process and the subsequent stiffening of large arteries in the animal model tested.

    Topics: Animals; Arteries; Calcinosis; Dietary Fats; Hypertrophy, Left Ventricular; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Superoxides; Thioctic Acid; Vascular Diseases; Vitamin K; Warfarin

2007
[Haemocholecyst: a rare complication of anticoagulant treatment].
    Annales francaises d'anesthesie et de reanimation, 2004, Volume: 23, Issue:7

    We report a case of a 50-year-old woman, taking antivitamin K for double mitro-aortic valvular replacement, having presented a clinical picture of acute cholecystitis with marked hypotension. The radiological and biologic exams showed a deep hypocoagulability, vesicular gallstones, a haemoperitoneum and retroperitoneal haematoma. After correction of biological anomalies, the patient was operated. The gallbladder was distended containing large clots and four stones without any evidence of perforation. One of the gallstones led to cystic duct obstruction. Haemocholecyst is a rare complication of anticoagulant therapy, which may occur in the setting of gallbladder stones. The usual complication was the vesicular perforation. In spite of its rarity, haemocholecyst should be suspected when an anticoagulant treated patient presents symptoms of acute cholecystis with or without haemorrhagic shock.

    Topics: Adult; Anticoagulants; Bile Ducts; Cholecystitis; Female; Heart Valve Prosthesis Implantation; Hematoma; Hemoperitoneum; Humans; Vascular Diseases; Vitamin K

2004
Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves.
    Arteriosclerosis, thrombosis, and vascular biology, 1998, Volume: 18, Issue:9

    High doses of warfarin cause focal calcification of the elastic lamellae in the media of major arteries and in aortic heart valves in the rat. Aortic calcification was first seen after 2 weeks of warfarin treatment and progressively increased in density at 3, 4, and 5 weeks of treatment. By 5 weeks, the highly focal calcification of major arteries could be seen on radiographs and by visual inspection of the artery. The calcification of arteries induced by warfarin is similar to that seen in the matrix Gla protein (MGP)-deficient mouse, which suggests that warfarin induces artery calcification by inhibiting gamma-carboxylation of MGP and thereby inactivating the putative calcification-inhibitory activity of the protein. Warfarin treatment markedly increased the levels of MGP mRNA and protein in calcifying arteries and decreased the level of MGP in serum. Warfarin treatment did not affect bone growth, overall weight gain, or serum calcium and phosphorus levels, and, because of the concurrent administration of vitamin K, prothrombin times and hematocrits were normal. The results indicate that the improved warfarin plus vitamin K treatment protocol developed in this study should provide a useful model to investigate the role of MGP in preventing calcification of arteries and heart valves.

    Topics: Animals; Arteries; Calcinosis; Calcium-Binding Proteins; Extracellular Matrix Proteins; Heart Valve Diseases; Male; Matrix Gla Protein; Rats; Rats, Sprague-Dawley; Vascular Diseases; Vitamin K; Warfarin

1998
Molecular determinants of arterial calcification.
    Annals of medicine, 1998, Volume: 30, Issue:6

    Calcification of extracellular matrix (ECM) can be either physiological or pathological. Physiological calcification (or mineralization) of ECM is restricted to bones, teeth and, to a lesser extent, growth plate cartilages. Pathological calcification appears often in the ECM of arteries where it is a frequent complication of atherosclerosis. However, calcification of the ECM of arteries is not restricted to atherosclerosis. Indeed, human diseases have been described that are characterized by calcification of the aortic media in the absence of any atherosclerotic lesions. The existence of these rare diseases, along with several mouse models recently generated and discussed below, indicates that the formation of atherosclerotic lesions and the calcification of the artery ECM are controlled by different genetic pathways. This emerging knowledge has implications for our understanding of ECM calcification beyond atherosclerosis.

    Topics: Animals; Arteries; Arteriosclerosis; Calcinosis; Calcium-Binding Proteins; Extracellular Matrix; Extracellular Matrix Proteins; Glycoproteins; Humans; Matrix Gla Protein; Mice; Osteoprotegerin; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Vascular Diseases; Vitamin K

1998
Vasospasm in the neonate: response to tolazoline infusion.
    Pediatrics, 1986, Volume: 77, Issue:3

    Topics: Catheters, Indwelling; Humans; Infant, Newborn; Infant, Premature, Diseases; Infusions, Intra-Arterial; Infusions, Parenteral; Male; Respiratory Distress Syndrome, Newborn; Tolazoline; Umbilical Arteries; Vascular Diseases; Vitamin K

1986
[Systematic medical observation and care of aged people suffering from diseases of the veins (author's transl)].
    Zeitschrift fur Alternsforschung, 1976, Volume: 31, Issue:4

    Topics: Acute Disease; Age Factors; Aged; Ambulatory Care; Anticoagulants; Female; Humans; Leg; Male; Middle Aged; Thromboembolism; Thrombophlebitis; Vascular Diseases; Veins; Vitamin K

1976
Jejunal diverticula as a source of massive upper gastrointestinal bleeding.
    Archives of surgery (Chicago, Ill. : 1960), 1967, Volume: 95, Issue:1

    Topics: Diverticulum; Gastrointestinal Hemorrhage; Gastrostomy; Humans; Jejunum; Male; Middle Aged; Vascular Diseases; Vitamin K; Warfarin

1967
Vitamin K-S (II) in liver disease. Effect of a new drug on coagulation defects.
    Archives of internal medicine, 1961, Volume: 107

    Topics: Antifibrinolytic Agents; Hemorrhagic Disorders; Humans; Liver Diseases; Vascular Diseases; Vitamin K

1961
[Relations between nutrition and vascular diseases from the experimental viewpoint. I].
    Die Medizinische, 1959, Jul-11, Volume: 4, Issue:27-28

    Topics: Arteriosclerosis; Humans; Lipids; Nutritional Status; Proteins; Vascular Diseases; Vitamin K; Vitamins

1959
[Diabetic vascular disease: a clinical case of cutaneous and visceral capillaropathy].
    Minerva medica, 1954, Oct-06, Volume: 45, Issue:80

    Topics: Capillaries; Diabetes Complications; Diabetic Angiopathies; Disease; Humans; Insulin; Psoriasis; Vascular Diseases; Vitamin K; Vitamins

1954
[Vitamins and vascular diseases].
    Hospital (Rio de Janeiro, Brazil), 1949, Volume: 36, Issue:1

    Topics: Cardiovascular Diseases; Humans; Vascular Diseases; Vitamin A; Vitamin K; Vitamins

1949